Literature DB >> 30194176

Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey.

Chukwuka Eze1, Olarn Roengvoraphoj1, Maurice Dantes1, Reem Abdo1, Lukas Käsmann2, Nina-Sophie Schmidt-Hegemann1, Claus Belka1,3, Farkhad Manapov1,3.   

Abstract

BACKGROUND/AIM: The general pattern of care regarding the application of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC) patients in Germany has not been previously evaluated. This survey was conducted to assess patterns of care. PATIENTS AND METHODS: Radiation oncology institutions in Germany were surveyed via an anonymous online questionnaire sent by e-mail to member institutions of the German Society for Radiation Oncology.
RESULTS: A total of 95 responses were received (29% response rate). Eighty-eight percent of all responders recommended a PCI total dose of 30Gy delivered in 15 daily fractions. Overall, 11 and 38% of the respondents applied PCI simultaneously with chemo- and radiotherapy, respectively. A quarter of respondents offered hippocampal-avoidance PCI and followed their patients with serial brain imaging.
CONCLUSION: PCI with a total dose of 30 Gy in 15 daily fractions, without neuropsychological testing and hippocampus-avoidance, delivered after completion of primary multimodal treatment remains standard in Germany. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  PCI; Patterns of care; SCLC; radiotherapy

Mesh:

Year:  2018        PMID: 30194176     DOI: 10.21873/anticanres.12851

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer.

Authors:  Leon SchnÖller; Lukas KÄsmann; Julian Taugner; Reem Abdo; Chukwuka Eze; Farkhad Manapov
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

2.  External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy.

Authors:  Lukas Käsmann; Reem Abdo; Chukwuka Eze; Maurice Dantes; Julian Taugner; Kathrin Gennen; Olarn Roengvoraphoj; Dirk Rades; Claus Belka; Farkhad Manapov
Journal:  Lung       Date:  2020-01-02       Impact factor: 2.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.